Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1943822

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2011

Description:
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2011', provides an overview of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections therapeutic pipeline. This report provides information on the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections. 'Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections.
- A review of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline depth and focus of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
 
Contents:


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Overview
Therapeutics Development
An Overview of Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics under Development by Companies
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics - Products under Development by Companies
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Development
F. Hoffmann-La Roche Ltd.
United Therapeutics Corporation
AlphaRx, Inc.
Sanofi-Aventis
AstraZeneca PLC
GlaxoSmithKline plc
Nektar Therapeutics
Takeda Pharmaceutical Company Limited
Albany Molecular Research, Inc.
Rib-X Pharmaceuticals, Inc.
Achillion Pharmaceuticals, Inc.
BioMarin Pharmaceutical Inc.
Toyama Chemical Co. Ltd
Warner Chilcott Limited
Wockhardt Limited
Avexa Limited
Paratek Pharmaceuticals, Inc.
Affinium Pharmaceuticals, Inc.
Helix BioMedix, Inc.
Lorus Therapeutics Inc
Basilea Pharmaceutica Ltd.
Biota Holdings Limited
Oragenics, Inc.
CytoGenix, Inc.
Dongwha Pharm Co., Ltd.
Theravance, Inc.
CrystalGenomics, Inc.
Phynova Group Ltd
Syntopix Group Plc
PolyMedix, Inc.
e-Therapeutics plc
Piramal Life Sciences Limited
Achaogen Inc.
Immupharma Plc
MerLion Pharmaceuticals Pte Ltd
MicuRx Pharmaceuticals, Inc.
Destiny Pharma Ltd.
Nitric Biotherapeutics, Inc.
NovaDigm Therapeutics, Inc.
Kenta Biotech Ltd.
aRigen Pharmaceuticals, Inc.
Nabriva Therapeutics AG
Inimex Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc.
Canopus BioPharma Incorporated
Cempra Pharmaceuticals, Inc.
Trius Therapeutics, Inc.
Lytix Biopharma AS
Medisyn Technologies, Inc.
PALUMED S.A.
Phico Therapeutics Ltd.
FAB Pharma
Durata Therapeutics Inc.
PharmaIN Corporation
Excelimmune, Inc.
UNeMed
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles
ACH-702 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dalbavancin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ACHN-490 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HB1345 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nemonoxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Phytobacx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MRX-I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lytixar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vancomycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anti-bacterial Drugs Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PGC Anti-MRSA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EP67 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SASPject PT1.2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MRSA Antibiotic - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anti-MRSA Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Staphguard - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antibacterial Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bactericidal Venom-Based Polypeptides - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lysin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics – Drug Profile Updates
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics - Discontinued Products
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Featured News
Oct 11, 2011: Lytix Biopharma Presents Data On LTX-109 At 51st Interscience Conference On Antimicrobial Agents And Chemotherapy
Sep 19, 2011: MGB Biopharma To Develop New Antibiotic Treatment For Resistant Infections
Sep 19, 2011: NovaDigm Presents Positive Phase I Safety And Immunogenicity Data For NDV-3 Vaccine
Sep 12, 2011: NovaDigm Therapeutics To Present Positive Phase I Clinical Data For NDV-3 Vaccine At ICAAC
Sep 12, 2011: NovaDigm Therapeutics To Present Positive Preclinical Data For NDV-3 Vaccine At ICAAC
Jun 01, 2011: Cempra Pharmaceuticals Profiles TAKSTA In Clinical Infectious Disease Supplement
May 31, 2011: Excelimmune Completes $10.5 Million Series B Financing
May 26, 2011: Lytix Biopharma Announces Successful Completion Of Two Phase I/IIa Studies Of Lytixar
May 26, 2011: Lytix Biopharma Announces Successful Completion Of Two Phase I/IIa Studies Of Lytixar
May 11, 2011: CrystalGenomics Completes Phase I MAD Study of Novel Antibiotic Candidate CG400549, And Prepares For Phase II Clinical Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1943822

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Nov 27, 2014
12:46:45 AM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2011

Web Address

http://www.researchandmarkets.com/reports/1943822

Office Code

SCOI7T

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User USD 500
Electronic (PDF) - Site License USD 1,000
Electronic (PDF) - Enterprisewide USD 1,500

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Nov 27, 2014
12:46:45 AM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)